Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Cell Culture and Lentiviral Transduction
2.2. Proteomics Analysis by SILAC Mass Spectrometry
2.3. RT-PCR and Quantitative Real-Time PCR
2.4. Patients
2.5. Sample Collection and Plasma Preparation
2.6. Immunohistochemistry
2.7. ELISA
2.8. Statistical Analysis
3. Results
3.1. Identification of Secretome Perturbations Induced by the Oncogenic KRASG12V Mutation in Human Pancreatic Cells
3.2. Expression of the Cancer-Associated Proteins in Pancreatic Cancer tissues
3.3. Plasma Levels of Candidate Biomarkers in PDAC Patients
3.4. Biomarker Panel in Early-Stage PDAC Patients and Patients with Low Levels of CA19-9
3.5. Biomarker Panel Expression in Plasma of Patients with Other Pancreatic Pathologies
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Mizrahi, J.D.; Surana, R.; Valle, J.W.; Shroff, R.T. Pancreatic cancer. Lancet 2020, 395, 2008–2020. [Google Scholar] [CrossRef]
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef] [PubMed]
- Chand, S.; O’Hayer, K.; Blanco, F.F.; Winter, J.M.; Brody, J.R. The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int. J. Biol. Sci. 2016, 12, 273–282. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hosein, A.N.; Dougan, S.K.; Aguirre, A.J.; Maitra, A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat. Cancer 2022, 3, 272–286. [Google Scholar] [CrossRef] [PubMed]
- Collisson, E.A.; Sadanandam, A.; Olson, P.; Gibb, W.J.; Truitt, M.; Gu, S.; Cooc, J.; Weinkle, J.; Kim, G.E.; Jakkula, L.; et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 2011, 17, 500–503. [Google Scholar] [CrossRef]
- Bertsimas, D.; Margonis, G.A.; Huang, Y.; Andreatos, N.; Wiberg, H.; Ma, Y.; Mcintyre, C.; Pulvirenti, A.; Wagner, D.; van Dam, J.L.; et al. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence–Based Model. JCO Clin. Cancer Inform. 2021, 5, 1220–1231. [Google Scholar] [CrossRef]
- Pereira, S.P.; Oldfield, L.; Ney, A.; Hart, P.A.; Keane, M.G.; Pandol, S.J.; Li, D.; Greenhalf, W.; Jeon, C.Y.; Koay, E.J.; et al. Early detection of pancreatic cancer. Lancet Gastroenterol. Hepatol. 2020, 5, 698–710. [Google Scholar] [CrossRef]
- Takikawa, T.; Kikuta, K.; Hamada, S.; Kume, K.; Miura, S.; Yoshida, N.; Tanaka, Y.; Matsumoto, R.; Ikeda, M.; Kataoka, F.; et al. Clinical features and prognostic impact of asymptomatic pancreatic cancer. Sci. Rep. 2022, 12, 4262. [Google Scholar] [CrossRef]
- Blackford, A.L.; Canto, M.I.; Klein, A.P.; Hruban, R.H.; Goggins, M. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. JNCI J. Natl. Cancer Inst. 2020, 112, 1162–1169. [Google Scholar] [CrossRef]
- Crinò, S.F.; Di Mitri, R.; Nguyen, N.Q.; Tarantino, I.; de Nucci, G.; Deprez, P.H.; Carrara, S.; Kitano, M.; Shami, V.M.; Fernández-Esparrach, G.; et al. Endoscopic Ultrasound–guided Fine-needle Biopsy with or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial. Gastroenterology 2021, 161, 899–909.e5. [Google Scholar] [CrossRef]
- Tempero, M.A.; Uchida, E.; Takasaki, H.; Burnett, D.A.; Steplewski, Z.; Pour, P.M. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987, 47, 5501–5503. [Google Scholar] [PubMed]
- Ballehaninna, U.K.; Chamberlain, R.S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J. Gastrointest. Oncol. 2012, 3, 105–119. [Google Scholar] [PubMed]
- O’Brien, D.P.; Sandanayake, N.S.; Jenkinson, C.; Gentry-Maharaj, A.; Apostolidou, S.; Fourkala, E.-O.; Camuzeaux, S.; Blyuss, O.; Gunu, R.; Dawnay, A.; et al. Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. Clin. Cancer Res. 2014, 21, 622–631. [Google Scholar] [CrossRef] [Green Version]
- Boyd, L.N.C.; Ali, M.; Kam, L.; Puik, J.R.; Rodrigues, S.M.F.; Zwart, E.S.; Daams, F.; Zonderhuis, B.M.; Meijer, L.L.; Le Large, T.Y.S.; et al. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach. Cancers 2022, 14, 344. [Google Scholar] [CrossRef] [PubMed]
- Wong, D.; Ko, A.H.; Hwang, J.; Venook, A.P.; Bergsland, E.K.; Tempero, M.A. Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Receiving Chemotherapy. Pancreas 2008, 37, 269–274. [Google Scholar] [CrossRef]
- Gold, D.V.; Modrak, D.E.; Ying, Z.; Cardillo, T.M.; Sharkey, R.M.; Goldenberg, D.M. New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer from Pancreatitis. J. Clin. Oncol. 2006, 24, 252–258. [Google Scholar] [CrossRef]
- Faça, V.M.; Song, K.S.; Wang, H.; Zhang, Q.; Krasnoselsky, A.L.; Newcomb, L.F.; Plentz, R.R.; Gurumurthy, S.; Redston, M.S.; Pitteri, S.J.; et al. A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development. PLoS Med. 2008, 5, e123. [Google Scholar] [CrossRef]
- Costello, E.; Greenhalf, W.; Neoptolemos, J.P. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 435–444. [Google Scholar] [CrossRef]
- Resovi, A.; Bani, M.R.; Porcu, L.; Anastasia, A.; Minoli, L.; Allavena, P.; Cappello, P.; Novelli, F.; Scarpa, A.; Morandi, E.; et al. Soluble stroma-related biomarkers of pancreatic cancer. EMBO Mol. Med. 2018, 10, e8741. [Google Scholar] [CrossRef]
- Skulimowski, A.; Durczyński, A.; Strzelczyk, J.; Hogendorf, P. Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: Meta-analysis and systematic review of literature. Biomarkers 2021, 26, 287–295. [Google Scholar] [CrossRef]
- Mantini, G.; Meijer, L.L.; Glogovitis, I.; In’t Veld, S.G.J.G.; Paleckyte, R.; Capula, M.; Le Large, T.Y.S.; Morelli, L.; Pham, T.V.; Piersma, S.R.; et al. Omics Analysis of Educated Platelets in Cancer and Benign Disease of the Pancreas. Cancers 2020, 13, 66. [Google Scholar] [CrossRef] [PubMed]
- De Oliveira, G.; Paccielli Freire, P.; Santiloni Cury, S.; de Moraes, D.; Santos Oliveira, J.; Dal-Pai-Silva, M.; do Reis, P.P.; Fran-cisco Carvalho, R. An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma. Cancers 2020, 12, 716. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mandili, G.; Curcio, C.; Bulfamante, S.; Follia, L.; Ferrero, G.; Mazza, E.; Principe, M.; Cordero, F.; Satolli, M.A.; Spadi, R.; et al. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. J. Immunother. Cancer 2020, 8, e001071. [Google Scholar] [CrossRef] [PubMed]
- Kane, L.; Mellotte, G.; Conlon, K.; Ryan, B.; Maher, S. Multi-Omic Biomarkers as Potential Tools for the Characterisation of Pancreatic Cystic Lesions and Cancer: Innovative Patient Data Integration. Cancers 2021, 13, 769. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.; Ploner, A.; Kordes, M.; Löhr, M.; Nilsson, M.; de Maturana, M.E.L.; Estudillo, L.; Renz, H.; Carrato, A.; Molero, X.; et al. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Int. J. Cancer 2021, 148, 2048–2058. [Google Scholar] [CrossRef] [PubMed]
- Butera, G.; Manfredi, M.; Fiore, A.; Brandi, J.; Pacchiana, R.; De Giorgis, V.; Barberis, E.; Vanella, V.; Galasso, M.; Scupoli, M.T.; et al. Tumor Suppressor Role of Wild-Type P53-Dependent Secretome and Its Proteomic Identification in PDAC. Biomolecules 2022, 12, 305. [Google Scholar] [CrossRef]
- Kartal, E.; Schmidt, T.S.B.; Molina-Montes, E.; Rodríguez-Perales, S.; Wirbel, J.; Maistrenko, O.M.; Akanni, W.A.; Alhamwe, B.A.; Alves, R.J.; Carrato, A.; et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 2022, 1–14. [Google Scholar] [CrossRef]
- Martínez-Bosch, N.; Cristóbal, H.; Iglesias, M.; Gironella, M.; Barranco, L.; Visa, L.; Calafato, D.; Jiménez-Parrado, S.; Earl, J.; Carrato, A.; et al. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. EBioMedicine 2022, 75, 103797. [Google Scholar] [CrossRef]
- De Sanctis, F.; Lamolinara, A.; Boschi, F.; Musiu, C.; Caligola, S.; Trovato, R.; Fiore, A.; Frusteri, C.; Anselmi, C.; Poffe, O.; et al. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. J. Immunother. Cancer 2022, 10, e003549. [Google Scholar] [CrossRef]
- Le Large, T.Y.; Mantini, G.; Meijer, L.L.; Pham, T.V.; Funel, N.; van Grieken, N.C.; Kok, B.; Knol, J.; van Laarhoven, H.W.; Piersma, S.R.; et al. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. JCI Insight 2020, 5, e138290. [Google Scholar] [CrossRef]
- Hruban, R.H.; Van Mansfeld, A.D.; Offerhaus, G.J.; Van Weering, D.H.; Allison, D.C.; Goodman, S.N.; Kensler, T.W.; Bose, K.K.; Cameron, J.L.; Bos, J.L. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol. 1993, 143, 545–554. [Google Scholar] [PubMed]
- Kitajima, S.; Thummalapalli, R.; Barbie, D.A. Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. Semin. Cell Dev. Biol. 2016, 58, 127–135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Buscail, L.; Bournet, B.; Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 153–168. [Google Scholar] [CrossRef] [PubMed]
- Pylayeva-Gupta, Y.; Grabocka, E.; Bar-Sagi, D. RAS oncogenes: Weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11, 761–774. [Google Scholar] [CrossRef] [Green Version]
- The Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 2017, 32, 185–203. [Google Scholar] [CrossRef] [Green Version]
- Collisson, E.A.; Bailey, P.; Chang, D.K.; Biankin, A.V. Molecular subtypes of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 207–220. [Google Scholar] [CrossRef]
- Thompson, E.D.; Roberts, N.J.; Wood, L.D.; Eshleman, J.R.; Goggins, M.G.; Kern, S.E.; Klein, A.P.; Hruban, R.H. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: Dramatic progress, but far to go. Mod. Pathol. 2020, 33, 2544–2563. [Google Scholar] [CrossRef]
- Noë, M.; Hong, S.-M.; Wood, L.D.; Thompson, E.D.; Roberts, N.J.; Goggins, M.G.; Klein, A.P.; Eshleman, J.R.; Kern, S.E.; Hruban, R.H. Pancreatic cancer pathology viewed in the light of evolution. Cancer Metastasis Rev. 2021, 40, 661–674. [Google Scholar] [CrossRef]
- Liu, N.; Furukawa, T.; Kobari, M.; Tsao, M.-S. Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Human Pancreas and Pancreatic Carcinoma. Am. J. Pathol. 1998, 153, 263–269. [Google Scholar] [CrossRef] [Green Version]
- Ouyang, H.; Mou, L.-J.; Luk, C.; Liu, N.; Karaskova, J.; Squire, J.; Tsao, M.-S. Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype. Am. J. Pathol. 2000, 157, 1623–1631. [Google Scholar] [CrossRef] [Green Version]
- Siddiqui, I.; Erreni, M.; Kamal, M.A.; Porta, C.; Marchesi, F.; Pesce, S.; Pasqualini, F.; Schiarea, S.; Chiabrando, C.; Mantovani, A.; et al. Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition. OncoImmunology 2018, 7, e1388485. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Locatelli, M.; Ferrero, S.; Boneschi, F.M.; Boiocchi, L.; Zavanone, M.; Gaini, S.M.; Bello, L.; Valentino, S.; Barbati, E.; Nebuloni, M.; et al. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J. Neuroimmunol. 2013, 260, 99–106. [Google Scholar] [CrossRef] [PubMed]
- Peri, G.; Introna, M.; Corradi, D.; Iacuitti, G.; Signorini, S.; Avanzini, F.; Pizzetti, F.; Maggioni, A.P.; Moccetti, T.; Metra, M.; et al. PTX3, A Prototypical Long Pentraxin, Is an Early Indicator of Acute Myocardial Infarction in Humans. Circulation 2000, 102, 636–641. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Knoflach, M.; Kiechl, S.; Mantovani, A.; Cuccovillo, I.; Bottazzi, B.; Xu, Q.; Xiao, Q.; Gasperi, A.; Mayr, A.; Kehrer, M.; et al. Pentraxin-3 as a Marker of Advanced Atherosclerosis Results from the Bruneck, ARMY and ARFY Studies. PLoS ONE 2012, 7, e31474. [Google Scholar] [CrossRef] [PubMed]
- Caldwell, M.E.; DeNicola, G.M.; Martins, C.P.; Jacobetz, M.A.; Maitra, A.; Hruban, R.H.; Tuveson, D.A. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene 2011, 31, 1599–1608. [Google Scholar] [CrossRef] [Green Version]
- Szklarczyk, D.; Gable, A.L.; Nastou, K.C.; Lyon, D.; Kirsch, R.; Pyysalo, S.; Doncheva, N.T.; Legeay, M.; Fang, T.; Bork, P.; et al. The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021, 49, D605–D612. [Google Scholar] [CrossRef]
- Gavazzi, F.; Capretti, G.; Giordano, L.; Ridolfi, C.; Spaggiari, P.; Sollai, M.; Carrara, S.; Nappo, G.; Bozzarelli, S.; Zerbi, A. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival. Dig. Liver Dis. 2021, in press. [Google Scholar] [CrossRef]
- Beatty, P.L.; van der Geest, R.; Hashash, J.G.; Kimura, T.; Gutkin, D.; Brand, R.E.; Finn, O.J. Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. Cancer Immunol. Immunother. 2016, 65, 771–778. [Google Scholar] [CrossRef]
- Deng, L.; Shang, Y.; Guo, S.; Liu, C.; Zhou, L.; Sun, Y.; Nie, Y.; Fan, D.; Lu, Y.; Guo, X. Ran GTPase protein promotes metastasis and invasion in pancreatic cancer by deregulating the expression of AR and CXCR4. Cancer Biol. Ther. 2014, 15, 1087–1093. [Google Scholar] [CrossRef] [Green Version]
- Elsheikh, S.; Kouzoukakis, I.; Fielden, C.; Li, W.; Lashin, S.E.; Khair, N.; Raposo, T.P.; Fadhil, W.; Rudland, P.; Aleskandarany, M.; et al. Ran GTPase is an independent prognostic marker in malignant melanoma which promotes tumour cell migration and invasion. J. Clin. Pathol. 2022, 75, 24–29. [Google Scholar] [CrossRef]
- Boudhraa, Z.; Carmona, E.; Provencher, D.; Mes-Masson, A.-M. Ran GTPase: A Key Player in Tumor Progression and Metastasis. Front. Cell Dev. Biol. 2020, 8, 345. [Google Scholar] [CrossRef] [PubMed]
- Park, J.; Matralis, A.N.; Berghuis, A.M.; Tsantrizos, Y.S. Human isoprenoid synthase enzymes as therapeutic targets. Front. Chem. 2014, 2, 50. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Han, S.; Li, X.; Xia, Y.; Yu, Z.; Cai, N.; Malwal, S.R.; Han, X.; Oldfield, E.; Zhang, Y. Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural-Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells. J. Med. Chem. 2019, 62, 10867–10896. [Google Scholar] [CrossRef] [PubMed]
- Fujiwara, D.; Tsubaki, M.; Takeda, T.; Tomonari, Y.; Koumoto, Y.-I.; Sakaguchi, K.; Nishida, S. Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells. Tumor Biol. 2017, 39, 1010428317734947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsubaki, M.; Fujiwara, D.; Takeda, T.; Kino, T.; Tomonari, Y.; Itoh, T.; Imano, M.; Satou, T.; Sakaguchi, K.; Nishida, S. The sensitivity of head and neck carcinoma cells to statins is related to the expression of their Ras expression status, and statin-induced apoptosis is mediated via suppression of the Ras/ERK and Ras/mTOR pathways. Clin. Exp. Pharmacol. Physiol. 2017, 44, 222–234. [Google Scholar] [CrossRef] [PubMed]
- Xu, Y.; Li, Z.; Jiang, P.; Wu, G.; Chen, K.; Zhang, X.; Li, X. The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer. Diagn. Pathol. 2015, 10, 211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tian, C.; Clauser, K.R.; Öhlund, D.; Rickelt, S.; Huang, Y.; Gupta, M.; Mani, D.R.; Carr, S.A.; Tuveson, D.A.; Hynes, R.O. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc. Natl. Acad. Sci. USA 2019, 116, 19609–19618. [Google Scholar] [CrossRef] [Green Version]
- Yoneura, N.; Takano, S.; Yoshitomi, H.; Nakata, Y.; Shimazaki, R.; Kagawa, S.; Furukawa, K.; Takayashiki, T.; Kuboki, S.; Miyazaki, M.; et al. Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. Int. J. Mol. Med. 2018, 42, 821–830. [Google Scholar]
- Juuti, A.; Nordling, S.; Louhimo, J.; Lundin, J.; Haglund, C. Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J. Clin. Pathol. 2004, 57, 1151–1155. [Google Scholar] [CrossRef] [Green Version]
- Geleta, B.; Tout, F.S.; Lim, S.C.; Sahni, S.; Jansson, P.J.; Apte, M.V.; Richardson, D.R.; Kovačević, Ž. Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1. J. Biol. Chem. 2022, 298, 101608. [Google Scholar] [CrossRef]
- Hagiwara, K.; Harimoto, N.; Yokobori, T.; Muranushi, R.; Hoshino, K.; Gantumur, D.; Yamanaka, T.; Ishii, N.; Tsukagoshi, M.; Igarashi, T.; et al. High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreatic Cancer. Ann. Surg. Oncol. 2020, 27, 924–930. [Google Scholar] [CrossRef] [PubMed]
- Balasenthil, S.; Huang, Y.; Liu, S.; Marsh, T.; Chen, J.; Stass, S.A.; Kukuruga, D.; Brand, R.; Chen, N.; Frazier, M.L.; et al. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. JNCI J. Natl. Cancer Inst. 2017, 109, djw341. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guess, C.M.; Quaranta, V. Defining the role of laminin-332 in carcinoma. Matrix Biol. 2009, 28, 445–455. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moon, Y.W.; Rao, G.; Kim, J.J.; Shim, H.-S.; Park, K.-S.; An, S.S.; Kim, B.; Steeg, P.S.; Sarfaraz, S.; Lee, L.C.; et al. LAMC2 enhances the metastatic potential of lung adenocarcinoma. Cell Death Differ. 2015, 22, 1341–1352. [Google Scholar] [CrossRef] [Green Version]
- Zhang, D.; Guo, H.; Feng, W.; Qiu, H. LAMC2 regulated by microRNA-125a-5p accelerates the progression of ovarian cancer via activating p38 MAPK signalling. Life Sci. 2019, 232, 116648. [Google Scholar] [CrossRef] [PubMed]
- Liang, Y.; Chen, X.; Wu, Y.; Li, J.; Zhang, S.; Wang, K.; Guan, X.; Yang, K.; Bai, Y. LncRNA CASC9 promotes esophageal squamous cell carcinoma metastasis through upregulating LAMC2 expression by interacting with the CREB-binding protein. Cell Death Differ. 2018, 25, 1980–1995. [Google Scholar] [CrossRef]
- Okada, Y.; Takahashi, N.; Takayama, T.; Goel, A. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma. Carcinogenesis 2021, 42, 546–556. [Google Scholar] [CrossRef]
- Garg, M.; Braunstein, G.; Koeffler, H.P. LAMC2 as a therapeutic target for cancers. Expert Opin. Ther. Targets 2014, 18, 979–982. [Google Scholar] [CrossRef] [Green Version]
- Kosanam, H.; Prassas, I.; Chrystoja, C.; Soleas, I.; Chan, A.; Dimitromanolakis, A.; Blasutig, I.; Rückert, F.; Gruetzmann, R.; Pilarsky, C.; et al. Laminin, gamma 2 (LAMC2): A Promising New Putative Pancreatic Cancer Biomarker Identified by Proteomic Analysis of Pancreatic Adenocarcinoma Tissues. Mol. Cell. Proteom. 2013, 12, 2820–2832. [Google Scholar] [CrossRef] [Green Version]
- Chan, A.; Prassas, I.; Dimitromanolakis, A.; Brand, R.E.; Serra, S.; Diamandis, E.P.; Blasutig, I.M. Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer. Clin. Cancer Res. 2014, 20, 5787–5795. [Google Scholar] [CrossRef] [Green Version]
- Islam, S.; Kitagawa, T.; Baron, B.; Abiko, Y.; Chiba, I.; Kuramitsu, Y. ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: An integrated bioinformatics analysis. Sci. Rep. 2021, 11, 10563. [Google Scholar] [CrossRef] [PubMed]
- Okada, Y.; Nishiwada, S.; Yamamura, K.; Sho, M.; Baba, H.; Takayama, T.; Goel, A. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. Eur. J. Cancer 2021, 146, 125–134. [Google Scholar] [CrossRef] [PubMed]
- Breviario, F.; D’Aniello, E.M.; Golay, J.; Peri, G.; Bottazzi, B.; Bairoch, A.; Saccone, S.; Marzella, R.; Predazzi, V.; Rocchi, M. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J. Biol. Chem. 1992, 267, 22190–22197. [Google Scholar] [CrossRef]
- Garlanda, C.; Hirsch, E.; Bozza, S.; Salustri, A.; De Acetis, M.; Nota, R.; Maccagno, A.; Riva, F.; Bottazzi, B.; Peri, G.; et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002, 420, 182–186. [Google Scholar] [CrossRef] [PubMed]
- Bottazzi, B.; Doni, A.; Garlanda, C.; Mantovani, A. An Integrated View of Humoral Innate Immunity: Pentraxins as a Paradigm. Annu. Rev. Immunol. 2010, 28, 157–183. [Google Scholar] [CrossRef] [PubMed]
- Camozzi, M.; Rusnati, M.; Bugatti, A.; Bottazzi, B.; Mantovani, A.; Bastone, A.; Inforzato, A.; Vincenti, S.; Bracci, L.; Mastroianni, D.; et al. Identification of an Antiangiogenic FGF2-binding Site in the N Terminus of the Soluble Pattern Recognition Receptor PTX3. J. Biol. Chem. 2006, 281, 22605–22613. [Google Scholar] [CrossRef] [Green Version]
- Ferrara, B.; Pignatelli, C.; Cossutta, M.; Citro, A.; Courty, J.; Piemonti, L. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Cancers 2021, 13, 4442. [Google Scholar] [CrossRef]
- Goulart, M.R.; Watt, J.; Siddiqui, I.; Lawlor, R.T.; Imrali, A.; Hughes, C.; Saad, A.; ChinAleong, J.; Hurt, C.; Cox, C.; et al. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. npj Precis. Oncol. 2021, 5, 61. [Google Scholar] [CrossRef]
- Kondo, S.; Ueno, H.; Hosoi, H.; Hashimoto, J.; Morizane, C.; Koizumi, F.; Tamura, K.; Okusaka, T. Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. Br. J. Cancer 2013, 109, 739–746. [Google Scholar] [CrossRef] [Green Version]
- Staubli, S.M.; Schäfer, J.; Rosenthal, R.; Zeindler, J.; Oertli, D.; Nebiker, C.A. The role of CRP and Pentraxin 3 in the prediction of systemic inflammatory response syndrome and death in acute pancreatitis. Sci. Rep. 2019, 9, 18340. [Google Scholar] [CrossRef]
Training Set | Validation Set | |
---|---|---|
Recruiting period | 2012–2014 | 2016–2017 |
PDAC patients n° | 78 | 122 |
Gender | F (41); M (37) | F (69); M (53) |
Age range | 38–86 | 38–83 |
Stage | ||
I/IIA | 15 | 14 |
IIB | 53 | 45 |
III | 0 | 19 |
IV | 8 | 34 |
ND 1 | 2 | 10 |
Resected/Total | 68/78 | 80/122 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kamal, M.A.; Siddiqui, I.; Belgiovine, C.; Barbagallo, M.; Paleari, V.; Pistillo, D.; Chiabrando, C.; Schiarea, S.; Bottazzi, B.; Leone, R.; et al. Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer. Cancers 2022, 14, 2653. https://doi.org/10.3390/cancers14112653
Kamal MA, Siddiqui I, Belgiovine C, Barbagallo M, Paleari V, Pistillo D, Chiabrando C, Schiarea S, Bottazzi B, Leone R, et al. Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer. Cancers. 2022; 14(11):2653. https://doi.org/10.3390/cancers14112653
Chicago/Turabian StyleKamal, Mohammad Azhar, Imran Siddiqui, Cristina Belgiovine, Marialuisa Barbagallo, Valentina Paleari, Daniela Pistillo, Chiara Chiabrando, Silvia Schiarea, Barbara Bottazzi, Roberto Leone, and et al. 2022. "Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer" Cancers 14, no. 11: 2653. https://doi.org/10.3390/cancers14112653